Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
T. Tada, B. M. Dcosta, M. Samanovic-Golden, R. S. Herati, A. Cornelius, M. J. Mulligan, N. R. Landau
This study evaluates the neutralizing activity of convalescent sera and BNT162b2 vaccine antibodies against SARS-CoV-2 variants, showing reduced efficacy against B.1.351 due to E484K mutation but overall maintained protection.
bioRxiv · Feb 5, 2021Microbiology